Reviewed: Heldin, CH, 2008-02-12 09:44:02 Regulation of receptor tyrosine kinase (RTK) activity is implicated in the control of almost all cellular functions. One of the best understood RTKs is epidermal growth factor receptor (EGFR). Growth factors can bind to EGFR and activate it to initiate signalling cascades within the cell. EGFRs can also be recruited to clathrin-coated pits which can be internalised into endocytic vesicles. From here, EGFRs can either be recycled back to the plasma membrane or directed to lysosomes for destruction.This provides a mechanism by which EGFR signalling is negatively regulated and controls the strength and duration of EGFR-induced signals. It also prevents EGFR hyperactivation as commonly seen in tumorigenesis.<br><br>The proto-oncogene Cbl can negatively regulate EGFR signalling. The Cbl family of RING-type ubiquitin ligases are able to poly-ubiquitinate EGFR, an essential step in EGFR degradation. All Cbl proteins have a unique domain that recognises phosphorylated tyrosine residues on activated EGFRs. They also direct the ubiquitination and degradation of activated EGFRs by recruiting ubiquitin-conjugation enzymes. Cbl proteins function by specifically targeting activated EGFRs and mediating their down-regulation, thus providing a means by which signaling processes can be negatively regulated.<br><br>Cbl also promotes receptor internalization via it's interaction with an adaptor protein, CIN85 (Cbl-interacting protein of 85kDa). CIN85 binds to Cbl via it's SH3 domain and is enhanced by the EGFR-induced tyrosine phosphorylation of Cbl. The proline-rich region of CIN85 interacts with endophilins which are regulatory components of clathrin-coated vesicles (CCVs). Endophilins bind to membranes and induce membrane curvature, in conjunction with other proteins involved in CCV formation. The rapid recruitment of endophilin to the activated receptor complex by CIN85 is the mechanism which controls receptor internalization. Authored: Castagnoli, L, 2006-10-10 13:09:34

http://purl.obolibrary.org/obo/HINO_0016082

Reviewed: Heldin, CH, 2008-02-12 09:44:02

Regulation of receptor tyrosine kinase (RTK) activity is implicated in the control of almost all cellular functions. One of the best understood RTKs is epidermal growth factor receptor (EGFR). Growth factors can bind to EGFR and activate it to initiate signalling cascades within the cell. EGFRs can also be recruited to clathrin-coated pits which can be internalised into endocytic vesicles. From here, EGFRs can either be recycled back to the plasma membrane or directed to lysosomes for destruction.This provides a mechanism by which EGFR signalling is negatively regulated and controls the strength and duration of EGFR-induced signals. It also prevents EGFR hyperactivation as commonly seen in tumorigenesis.

The proto-oncogene Cbl can negatively regulate EGFR signalling. The Cbl family of RING-type ubiquitin ligases are able to poly-ubiquitinate EGFR, an essential step in EGFR degradation. All Cbl proteins have a unique domain that recognises phosphorylated tyrosine residues on activated EGFRs. They also direct the ubiquitination and degradation of activated EGFRs by recruiting ubiquitin-conjugation enzymes. Cbl proteins function by specifically targeting activated EGFRs and mediating their down-regulation, thus providing a means by which signaling processes can be negatively regulated.

Cbl also promotes receptor internalization via it's interaction with an adaptor protein, CIN85 (Cbl-interacting protein of 85kDa). CIN85 binds to Cbl via it's SH3 domain and is enhanced by the EGFR-induced tyrosine phosphorylation of Cbl. The proline-rich region of CIN85 interacts with endophilins which are regulatory components of clathrin-coated vesicles (CCVs). Endophilins bind to membranes and induce membrane curvature, in conjunction with other proteins involved in CCV formation. The rapid recruitment of endophilin to the activated receptor complex by CIN85 is the mechanism which controls receptor internalization.

Authored: Castagnoli, L, 2006-10-10 13:09:34

Pubmed11283727

Reactome, http://www.reactome.org

Pubmed14641021

Pubmed15021893

EGFR downregulation

http://purl.obolibrary.org/obo/NCBITaxon_9606

HINO:0016082

EGFR downregulation

Reactome Database ID Release 43182971

GENE ONTOLOGYGO:0042059

ReactomeREACT_12484

http://purl.obolibrary.org/obo/INO_0000021

http://purl.obolibrary.org/obo/HINO_0009820

http://purl.obolibrary.org/obo/HINO_0009825

http://purl.obolibrary.org/obo/HINO_0009823

http://purl.obolibrary.org/obo/HINO_0009829

http://purl.obolibrary.org/obo/HINO_0009824

http://purl.obolibrary.org/obo/HINO_0009826

http://purl.obolibrary.org/obo/HINO_0009515

http://purl.obolibrary.org/obo/HINO_0009516

http://purl.obolibrary.org/obo/HINO_0009832

http://purl.obolibrary.org/obo/HINO_0009834

http://purl.obolibrary.org/obo/HINO_0009815

http://purl.obolibrary.org/obo/HINO_0009817

http://purl.obolibrary.org/obo/HINO_0009873

http://purl.obolibrary.org/obo/HINO_0009876

http://purl.obolibrary.org/obo/HINO_0009871

http://purl.obolibrary.org/obo/HINO_0009868

http://purl.obolibrary.org/obo/HINO_0009865

http://purl.obolibrary.org/obo/HINO_0009869

http://purl.obolibrary.org/obo/HINO_0009867